The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

Leukemia Research

Volumn 36, Issue 5, 2012, Pages 525-536

  Platzbecker, Uwe ^a   Hofbauer, Lorenz C ^a   Ehninger, Gerhard ^a   Hölig, Kristina ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Iron overload; MDS; Quality of life; Transfusions

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; BLOOD TRANSFUSION REACTION; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC ASPECT; ERYTHROCYTE TRANSFUSION; FATIGUE; FEVER; HEALTH CARE COST; HUMAN; INFECTION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MORTALITY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL FACTOR; SYSTEMATIC REVIEW; THERAPY EFFECT;

ANEMIA; ERYTHROCYTE TRANSFUSION; FATIGUE; HEMOGLOBINS; HUMANS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE;

EID: 84858748853     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.01.006     Document Type: Review

References (79)

1. Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 2006, 106:2087-2094.
2. Alessandrino E.P., Amadori S., Barosi G., Cazzola M., Grossi A., Liberato L.N., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002, 87:1286-1306.
3. Greenberg P.L. Current therapeutic approaches for patients with myelodysplastic syndromes. Br J Haematol 2010, 150:131-143.
4. Heptinstall K. Quality of life (QoL) in myelodysplastic syndromes (MDS): an update of results from US & European patient forums [abstract]. Leuk Res 2007, 31(Suppl. 1):S107.
5. Kelaidi C., Stamatoullas A., Beyne-Rauzy O., Raffoux E., Quesnel B., Guerci A., et al. Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica 2010, 95:892-899.
6. Bowen D.T. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients. Semin Oncol 2005, 32(4 Suppl. 5):S16-S23.
7. Hellström-Lindberg E., Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol 2008, 45:14-22.
8. Steensma D.P., Bennett J.M. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006, 81:104-130.
9. Vamvakas E.C., Blajchman M.A. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009, 113:3406-3417.
10. Funk M.B., Gunay S., Lohmann A., Henseler O., Keller-Stanislawski B. Evaluation of measures aimed to reduce serious adverse transfusion reactions (hemovigilance data from 1997 to 2008). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010, 53:347-356. [Article in German].
11. Chelemer S.B., Prato B.S., Cox P.M., O'Connor G.T., Morton J.R. Association of bacterial infection and red blood cell transfusion after coronary artery bypass surgery. Ann Thorac Surg 2002, 73:138-142.
12. Vamvakas E.C. Meta-analysis of randomized controlled trials comparing the risk of postoperative infection between recipients of allogeneic and autologous blood transfusion. Vox Sang 2002, 83:339-346.
13. Hendrickson J.E., Hillyer C.D. Noninfectious serious hazards of transfusion. Anesth Analg 2009, 108:759-769.
14. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990, 30:583-590.
15. Blajchman M.A., Beckers E.A., Dickmeiss E., Lin L., Moore G., Muylle L. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005, 19:259-272.
16. Vamvakas E.C., Blajchman M.A. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010, 24:77-124.
17. Cazzola M., Anderson J.E., Ganser A., Hellström-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica 1998, 83:910-935.
18. Goldberg S.L., Chen E., Corral M., Guo A., Mody-Patel N., Pecora A.L., et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010, 28:2847-2852.
19. Gupta P., LeRoy S.C., Luikart S.D., Bateman A., Morrison V.A. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. Leuk Res 1999, 23:953-959.
20. Stiegler G., Sperr W., Lorber C., Fabrizii V., Höcker P., Panzer S. Red cell antibodies in frequently transfused patients with myelodysplastic syndrome. Ann Hematol 2001, 80:330-333.
21. Steensma D.P., Heptinstall K.V., Johnson V.M., Novotny P.J., Sloan J.A., Camoriano J.K., et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res 2008, 32:691-698.
22. Malcovati L., Della Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23:7594-7603.
23. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
24. Demirkan F., Alacacioglu I., Piskin O., Ozsan H.G., Akinci B., Ozcan A.M., et al. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma 2007, 48:1372-1378.
25. Wei J., Zhou X.F., Zhou J.F., Chen Y. Analysis of WHO-based Prognostic Scoring System (WPSS) of myelodysplastic syndrome and its comparison with International Prognostic Scoring System (IPSS) in 100 Chinese patients. Chin J Cancer Res 2009, 21:50-55.
26. Cermak J., Kacirkova P., Mikulenkova D., Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009, 33:1469-1474.
27. Durairaj S., Chew S., Hyslop A., Keenan N., Groves M.J., Tauro S. Predicted costs of iron-chelators in myelodysplastic syndromes: a 10-year analysis based on actual prevalence and red cell transfusion rates. Am J Hematol 2011, 86:406-410.
28. Pereira A., Nomdedeu M., Aguilar J.L., Belkaid M., Carrió A., Cobo F., et al. Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support. Am J Hematol 2011, 86:245-250.
29. Takatoku M., Uchiyama T., Okamoto S., Kanakura Y., Sawada K., Tomonaga M., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007, 78:487-494.
30. Lindquist K.J., Danese M.D., Mikhael J., Knopf K.B., Griffiths R.I. Health care utilization and mortality among elderly patients with myelodysplastic syndromes. Ann Oncol 2011, 22:1181-1188.
31. Oliva E.N., Dimitrov B.D., Benedetto F., D'Angelo A., Nobile F. Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. Leuk Res 2005, 29:1217-1219.
32. Jädersten M., Malcovati L., Dybedal I., Della Porta M.G., Invernizzi R., Montgomery S.M., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
33. Alessandrino E.P., Della Porta M.G., Bacigalupo A., Van Lint M.T., Falda M., Onida F., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902.
34. Kim Y.R., Kim J.S., Cheong J.W., Song J.W., Min Y.H. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies. Acta Haematol 2008, 120:182-189.
35. Alessandrino E.P., Della Porta M.G., Bacigalupo A., Malcovati L., Angelucci E., Van Lint M.T., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010, 95:476-484.
36. Platzbecker U., Bornhäuser M., Germing U., Stumpf J., Scott B.L., Kröger N., et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008, 14:1217-1225.
37. Delea T.E., Hagiwara M., Phatak P.D. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009, 25:139-147.
38. Remacha A.F., Arrizabalaga B., Del Cañizo C., Sanz G., Villegas A. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements. Ann Hematol 2010, 89:147-154.
39. Raptis A., Duh M.S., Wang S.T., Dial E., Fanourgiakis I., Fortner B., et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 2010, 50:190-199.
40. Delforge M., Selleslag D., Triffet A., Mineur P., Bries G., Graux C., et al. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Ann Hematol 2011, 90:655-666.
41. Giagounidis A., Leto di Priolo S., Ille S., Fenaux P. A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS. Ann Hematol 2011, 90:667-673.
42. Chee C.E., Steensma D.P., Wu W., Hanson C.A., Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008, 83:611-613.
43. Jaeger M., Aul C., Söhngen D., Germing U., Schneider W. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes. Beitr Infusionsther 1992, 30:464-468. [Article in German].
44. Ho C.H. The effect of transfusion on cardiac function in patients with chronic anemia. Transfusion 1997, 37:1066-1069.
45. Konen E., Ghoti H., Goitein O., Winder A., Kushnir T., Eshet Y., et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2* technique. Am J Hematol 2007, 82:1013-1016.
46. Di Tucci A.A., Matta G., Deplano S., Gabbas A., Depau C., Derudas D., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008, 93:1385-1388.
47. Chacko J., Pennell D.J., Tanner M.A., Hamblin T.J., Wonke B., Levy T., et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007, 138:587-593.
48. Au W., Lam W., Chu W., Tam S., Wong W., Chan H., et al. A pilot MRI study of organ specific hemosiderosis and functional correlation in Chinese patients with myelodysplasia and aplastic anemia with raised ferritin levels. Hematol Oncol 2008, 26:225-228.
49. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010, 34:864-870.
50. Szende A., Schaefer C., Goss T.F., Heptinstall K., Knight R., Lübbert M., et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes 2009, 7:81.
51. Goss T.F., Szende A., Schaefer C., Totten P.J., Knight R., Jädersten M., et al. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006, 13(Suppl.):17-25.
52. Caocci G., Baccoli R., Ledda A., Littera R., La Nasa G. A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue. Leuk Res 2007, 31:249-252.
53. Jansen A.J., Essink-Bot M.L., Beckers E.A., Hop W.C., Schipperus M.R., Van Rhenen D.J. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003, 121:270-274.
54. Hellström-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120:1037-1046. Scandinavian MDS Group.
55. Spiriti M.A., Latagliata R., Niscola P., Cortelezzi A., Francesconi M., Ferrari D., et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005, 84:167-176.
56. Stasi R., Abruzzese E., Lanzetta G., Terzoli E., Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005, 16:1921-1927.
57. Casadevall N., Durieux P., Dubois S., Hemery F., Lepage E., Quarré M.C., et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004, 104:321-327.
58. Frytak J.R., Henk H.J., De Castro C.M., Halpern R., Nelson M. Estimation of economic costs associated with transfusion dependence in adults with MDS. Curr Med Res Opin 2009, 25:1941-1951.
59. Kühne F., Mittendorf T., Germing U., Tesch H., Weinberg R., Grabenhorst U., et al. Cost of transfusion-dependent myelodysplastic syndrome (MDS) from a German payer's perspective. Ann Hematol 2010, 89:1239-1247.
60. Greenberg P.L., Cosler L.E., Ferro S.A., Lyman G.H. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008, 6:942-953.
61. O'Brien J.A., Caro J. Managing myelodysplastic syndromes with supportive therapy in elderly persons. Drug Benefit Trends 2005, 17:341-351.
62. Minuk L., Chin-Yee I., Hibbert A., Chan D., Xenocostas A. Red blood cell transfusion and chemotherapy administration: a study of resource utilization. Community Oncol 2008, 5:598-603.
63. Singh S., Kumar A. Leukocyte depletion for safe blood transfusion. Biotechnol J 2009, 4:1140-1151.
64. Singer S.T., Wu V., Mignacca R., Kuypers F.A., Morel P., Vichinsky E.P. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000, 96:3369-3373.
65. Schonewille H., van de Watering L.M., Brand A. Additional red blood cell alloantibodies after blood transfusion in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures?. Transfusion 2006, 46:630-635.
66. Pullarkat V., Blanchard S., Tegtmeier B., Dagis A., Patane K., Ito J., et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008, 42:799-805.
67. Armand P., Kim H.T., Cutler C.S., Ho V.T., Koreth J., Alyea E.P., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
68. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008, 88:24-29.
69. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 2009, 114:5251-5255.
70. Altes A., Remacha A.F., Sarda P., Sancho F.J., Sureda A., Martino R., et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 2004, 34:505-509.
71. Malcovati L., Della Porta M.G., Strupp C., Ambaglio I., Kuendgen A., Nachtkamp K., et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011, [Epub ahead of print]. 10.3324/haematol.2011.044602.
72. Pinchon D.J., Stanworth S.J., Dorée C., Brunskill S., Norfolk D.R. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol 2009, 84:671-677.
73. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
74. Kornblith A.B., Herndon J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., et al. Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441-2452.
75. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
76. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
77. Fenaux P., Giagounidis A., Selleslag D., Beyne-Rauzy O., Mufti G., Mittelman M., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118:3765-3776.
78. Pan F., Peng S., Fleurence R., Linnehan J.E., Knopf K., Kim E. Economic analysis of decitabine versus best supportive care in the treatment of Intermediate- and High-risk myelodysplastic syndromes from a US payer perspective. Clin Ther 2010, 32:2444-2456.
79. Zou D., Risebrough N., Buckstein R., Kim T., Levy A. Cost-effectiveness in Canada of azacitidine for the treatment of higher risk myelodysplastic syndromes and acute myeloid leukemia. Leuk Res 2011, 35(Suppl. 1):S108. [Abstract].